Discovery of a novel RORγ antagonist with skin-restricted exposure for topical treatment of mild to moderate psoriasis

Abstract Clinical success of IL-17/IL-23 pathway biologics for the treatment of moderate to severe psoriasis suggests that targeting RORγt, a master regulator for the proliferation and function of Th17 cells, could be an effective alternative. However, oral RORγ antagonists (VTP43742, TAK828) with h...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Suxing Liu, Dong Liu, Ru Shen, Di Li, Qiyue Hu, Yinfa Yan, Jiakang Sun, Fengqi Zhang, Hong Wan, Ping Dong, Jun Feng, Rumin Zhang, Jing Li, Lianshan Zhang, Weikang Tao
Format: article
Langue:EN
Publié: Nature Portfolio 2021
Sujets:
R
Q
Accès en ligne:https://doaj.org/article/778a56f614ee48949e2ce625b054df42
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!